1. Refractory ventricular fibrillation treated with esmolol
- Author
-
Sang O Park, Gyu Chong Cho, Seung Min Park, Young-Hwan Lee, Kui Ja Lee, Yong Hun Min, Won Woong Lee, You Dong Sohn, Jeong Yeol Seo, Dong Hyuk Shin, Young Taeck Oh, and Hee Cheol Ahn
- Subjects
Male ,medicine.medical_specialty ,Defibrillation ,medicine.medical_treatment ,Drug Resistance ,Electric Countershock ,030204 cardiovascular system & hematology ,Emergency Nursing ,Return of spontaneous circulation ,Loading dose ,Drug Administration Schedule ,Propanolamines ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Internal medicine ,medicine ,Humans ,Cardiopulmonary resuscitation ,Prospective cohort study ,Aged ,Retrospective Studies ,Neurologic Examination ,business.industry ,030208 emergency & critical care medicine ,Middle Aged ,medicine.disease ,Esmolol ,Adrenergic beta-1 Receptor Antagonists ,Survival Analysis ,Cardiopulmonary Resuscitation ,Treatment Outcome ,Anesthesia ,Ventricular Fibrillation ,Ventricular fibrillation ,Emergency Medicine ,Cardiology ,Female ,Drug Monitoring ,Cardiology and Cardiovascular Medicine ,business ,Out-of-Hospital Cardiac Arrest ,medicine.drug - Abstract
Aims This study aimed to evaluate the effects of esmolol treatment for patients with refractory ventricular fibrillation (RVF) in out-of-hospital cardiac arrest (OHCA). Methods This single-centre retrospective pre-post study evaluated patients who were treated between January 2012 and December 2015. Some patients had received esmolol (loading dose: 500μg/kg, infusion: 0-100μg/kg/min) for RVF (≥3 defibrillation attempts), after obtaining consent from the patient's guardian. Results Twenty-five patients did not receive esmolol (the control group), and 16 patients received esmolol. Sustained return of spontaneous circulation (ROSC) was significantly more common in the esmolol group, compared to the control group (56% vs. 16%, p=0.007). Survival and good neurological outcomes at 30 days, 3 months and at 6 months were >2-fold better in the esmolol group, compared to the control group, although these increases were not statistically significant. Conclusions The findings of our study suggest that administration of esmolol may increase the rate of sustained ROSC and ICU survival among patients with RVF in OHCA. Further larger-scale, prospective studies are necessary to determine the effect of esmolol for RVF in OHCA.
- Published
- 2016
- Full Text
- View/download PDF